Clinical characteristics of subjects. No differences were statistically significant.
| Characteristic | IFX, n = 9 | RTX, n = 5 |
|---|---|---|
| Female, n | 9/9 | 4/5 |
| Age, yrs, mean (SD) | 54.7 (14.5) | 35.4 (7.5) |
| Disease duration, yrs, mean (SD) | 6.1 (6.7) | 3.2 (2.5) |
| RF-positive, n | 5/9 | 5/5 |
| Baseline DAS28, median (IQR) | 6.0 (5.0–7.0) | 5.6 (4.0–7.2) |
| Baseline CRP, median (IQR) | 37.4 (8.5–66.3) | 42.7 (13.7–71.7) |
| No. failed DMARD, median (range) | 1 (0–2) | 2 (1–4) |
IFX: infliximab; RTX: rituximab; RF: rheumatoid factor; DAS28: Disease Activity Score at 28 joints; IQR: interquartile range; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drugs.